A5084870834- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Eosinophilic Disorders and Syndromes
- Cancer Treatment and Pharmacology
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Cancer Mechanisms and Therapy
- Helicobacter pylori-related gastroenterology studies
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Colorectal and Anal Carcinomas
- Cancer-related gene regulation
- Renal cell carcinoma treatment
Hallym University Medical Center
2016-2025
Hallym University Sacred Heart Hospital
2016-2025
Hallym University
2014-2024
Beijing University of Chinese Medicine
2024
Second Affiliated Hospital of Dalian Medical University
2023
Robert Bosch (Germany)
2021
Micron (United States)
2021
Micron Biomedical (United States)
2021
Harm Reduction Services
2021
Shandong Provincial Hospital
2019
Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared efficacy olaparib plus paclitaxel (olaparib/paclitaxel) alone in patients recurrent or metastatic gastric and assessed whether ATM expression is predictive improved clinical outcome for olaparib/paclitaxel. Patients Methods In this phase II, double-blind study (Study...
PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings perioperative European phase III studies, the PRODIGY study (ClinicalTrials.gov identifier: NCT01515748 ) investigated whether neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery adjuvant could improve outcomes versus treatment Korean patients with LAGC. PATIENTS AND METHODS Patients 20-75 years of age, Eastern Cooperative...
Adjuvant chemotherapy and chemoradiotherapy are some of the standards care for gastric cancer (GC). The chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant regimens in patients with D2-resected, stage II or III, node-positive GC.The ARTIST compared, a 1:1:1 ratio, three regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 off) 1 year, (2 on/1 week plus oxaliplatin 130 mg/m2 every 3 (SOX) 6 months, SOX 45 Gy (SOXRT). Randomization was stratified according to surgery...
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total 90 patients with a follow-up ≥12 months were analyzed. After median 26.6 after discontinuation, 37 lost major molecular response. probability sustained response at 12 24 62.2% 58.5%, respectively. All who retreated therapy 16.9 months, all achieved again 3.9 resuming therapy. We observed newly developed or worsened musculoskeletal pain pruritus in 27 (30%)...
Abstract In this multi-center phase II trial, we evaluated the efficacy and safety of a quadruplet regimen (pembrolizumab, trastuzumab, doublet chemotherapy) as first-line therapy for unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) (NCT02901301). The primary endpoints were recommended dose (RP2D) Ib objective response rate (ORR) II. secondary included progression-free survival (PFS), overall (OS), duration response, time to...
Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated safety and efficacy of trastuzumab combined with ramucirumab paclitaxel as second-line treatment HER2-positive G/GEJ cancer.Patients cancer who progressed after trastuzumab-containing were enrolled from five centers in Republic Korea. Patients administered a 28-day cycle (once on days...
JCO
This randomised multicentre phase II study was conducted to investigate the activity and safety of two oral fluoropyrimidines, capecitabine or S-1, in elderly patients with advanced gastric cancer (AGC). Elderly (⩾65 years) chemo-naive AGC were randomly assigned receive 1250 mg m−2 times daily on days 1–14 every 3 weeks S-1 40–60 according body surface area 1–28 6 weeks. Ninety-six enrolled 91 (N=46) (N=45). Overall response rate, primary end point, 27.2% (95% CI, 14.1–40.4, 12 44 assessable...
BackgroundThis study explored the impact of genetic polymorphisms in cytochrome P450 (CYP) enzymes and transporters on plasma trough concentration imatinib mesylate (IM) clinical response chronic myeloid leukemia (CML).Patients methodsIn total, 82 patients with CML who had been administered 400 mg IM daily for over 6 months were genotyped 11 single-nucleotide nine genes (CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC22A1, SLC22A2 ABCG2) using blood samples. The responses assessed after...
4001 Background: Adjuvant chemotherapy and/or chemoradiotherapy have been the standard of care in GC for years, supported by randomized trials. We compared efficacy different regimens and patients with D2-resected, stage II/III, node-positive GC. Methods: From Feb 2013 through Nov 2018, we randomly assigned, a 1:1:1 ratio, pathologically-staged II or III, node-positive, D2-resected GC, to receive adjuvant S-1 (40-60 mg twice daily 4-weeks-on/2-weeks-off) one year, (2-weeks-on/1-week-off)...
Purpose We compared two induction regimens, idarubicin (12 mg/m 2 /d for 3 days) versus high-dose daunorubicin (90 days), in young adults with newly diagnosed acute myeloid leukemia (AML). Patients and Methods A total of 299 patients (149 randomly assigned to cytarabine plus [AI] 150 [AD]) were analyzed. All received (200 7 days). Results Complete remission (CR) was induced 232 (77.6%), no difference CR rates between the AI AD arms (80.5% v 74.7%, respectively; P = .224). At a median...
Abstract Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase myeloid leukemia (CML-CP) patients newly diagnosed or with insufficient response to other TKIs. This study was conducted evaluate the efficacy and safety of radotinib as first-line therapy CML-CP. Experimental Design: multinational, open-label assigned (1:1:1) one two twice-daily doses, imatinib daily. The primary endpoint major molecular (MMR) by 12 months....
Radotinib (IY5511HCL), a novel and selective BCR-ABL1 tyrosine kinase inhibitor, has shown pre-clinical phase I activity safety in chronic myeloid leukemia. This II study investigated the efficacy of radotinib Philadelphia chromosome-positive phase-chronic leukemia patients with resistance and/or intolerance to inhibitors. Patients received 400 mg twice daily for 12 cycles based on results from trial. The primary end point was rate major cytogenetic response by months. A total 77 were...
Although recent studies have suggested that cessation of imatinib (IM) in chronic myeloid leukemia patients can be associated with sustained response, further validation is needed to explore predictive factors. In a prospective, multicenter study, phase were eligible for IM therapy after more than 3 years if they had no detectable BCR-ABL1 transcript at least 2 years. A total 48 median age 47 (19-74 years) enrolled. Twenty received post-transplant relapse. After follow-up 15.8 months...
218 Background: We report the updated clinical data and molecular profiling results of a multi-institutional phase Ib/II trial triple combination (pembrolizumab, trastuzumab, chempotherapy) as first line therapy for HER2 positive advanced gastric gastroesophageal junction (AGC/GEJ) cancer. (PANTHERA trial; NCT02901301). Methods: Pembrolizumab 200mg IV D1, Trastuzumab 6mg/kg (after 8mg/kg load) Capecitabine 1000mg/m 2 bid D1-14, Cisplatin 80mg/m D1 every 3 weeks was selected recommended II...
426 Background: Regulatory T-cells (T regs ) suppress anti-tumor immunity by migrating into tumors via CCL17/CCL22 chemokines binding to CCR4. FLX475 (tivumecirnon), a selective CCR4 antagonist, inhibits T reg recruitment, enhancing the effector T-cell eff response in tumor microenvironment. Preclinical studies demonstrate that increases /T ratio and boosts efficacy, both as monotherapy combination with checkpoint inhibitors (CPI). Here, we present findings on safety efficacy of...
Functional iron-deficiency anemia (FIDA) is a side effect of many cancer treatments, occurring when chemotherapy drugs damage bone marrow cells, which are responsible for producing red blood due to the myelosuppressive effects chemotherapy, or itself. This study was performed compare darbepoetin alfa alone, in combination with ferric derisomaltose patients FIDA, and elucidate mechanism underlying F36E cells. cells treated showed increased cell viability. AML GC alfa, derisomaltose, plus no...